COCH Envoy Medical, Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies · Nasdaq · SEC CIK 1840877 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY11.1%
TTM net income YoY4.3%
TTM EPS YoY164.4%
Revenue 3-yr CAGR-1.4%
Net income 3-yr CAGR—
Margins
Gross margin-352.8%
Operating margin-10,151.5%
Net margin-9,026.4%
FCF margin—
EBITDA margin-10,020.8%
Returns
ROE—
ROA-152.5%
ROIC (approx.)—
Asset turnover0.02x
Leverage & solvency
Liabilities / assets106.0%
Debt / equity—
Current ratio1.21x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.07x
Accruals ratio10.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $66,000 | $51,000 | $39,000 | $75,000 | $42,000 | $78,000 | $46,000 | $42,000 |
| Cost of revenue | $244,000 | $278,000 | $313,000 | $211,000 | $203,000 | $234,000 | $226,000 | $157,000 |
| Gross profit | -$178,000 | -$227,000 | -$274,000 | -$136,000 | -$161,000 | -$156,000 | -$180,000 | -$115,000 |
| R&D expense | $3.08M | $3.13M | $3.64M | $4.55M | $2.70M | $2.48M | $2.75M | $2.47M |
| SG&A expense | $2.12M | $2.03M | $1.88M | $1.60M | $2.00M | $2.07M | $1.82M | $1.42M |
| Operating income | -$5.54M | -$5.57M | -$5.96M | -$6.38M | -$5.26M | -$5.07M | -$5.11M | -$4.52M |
| Interest expense | — | — | — | $0 | $471,000 | $624,000 | $495,000 | $384,000 |
| Net income | -$3.93M | -$5.98M | -$4.35M | -$6.59M | -$6.48M | -$5.69M | -$5.00M | -$4.62M |
| EBITDA | -$5.46M | -$5.50M | -$5.89M | -$6.30M | -$5.19M | -$4.99M | -$5.05M | -$4.48M |
| EPS (basic) | -0.50 | -0.07 | -0.08 | — | -3.55 | -0.32 | -0.29 | — |
| EPS (diluted) | -0.50 | -0.07 | -0.08 | — | -3.55 | -0.32 | -0.29 | — |
| Weighted avg. shares (diluted) | 10.43M | 104.04M | 68.93M | — | 2.19M | 21.38M | 21.33M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $14.57M | $19.68M | $25.25M | $3.74M | $3.56M | $5.29M | $5.31M | $5.48M |
| Receivables | $51,000 | $49,000 | $31,000 | $34,000 | $35,000 | $43,000 | $42,000 | $38,000 |
| Inventory | $1.51M | $1.58M | $1.49M | $1.55M | $1.64M | $1.59M | $1.66M | $1.71M |
| Current assets | $17.26M | $21.92M | $27.68M | $6.28M | $5.76M | $7.51M | $8.31M | $8.90M |
| PP&E, net | $854,000 | $921,000 | $962,000 | $1.03M | $1.12M | $1.14M | $1.22M | $1.27M |
| Total assets | $19.16M | $23.95M | $29.82M | $8.56M | $8.18M | $9.90M | $10.38M | $11.54M |
| Current liabilities | $14.27M | $12.63M | $12.21M | $11.56M | $8.99M | $8.00M | $7.59M | $7.54M |
| Total liabilities | $20.30M | $20.25M | $19.27M | $20.32M | $15.71M | $39.76M | $34.61M | $30.38M |
| Shareholders' equity | -$1.53M | $3.30M | $10.16M | -$12.16M | -$7.66M | -$29.86M | -$24.22M | -$18.84M |
| Shares outstanding | — | — | — | — | — | 21.52M | 21.33M | 21.33M |
| Cash flow statement | ||||||||
| Operating cash flow | -$5.03M | -$5.46M | -$6.06M | -$5.68M | -$4.33M | -$4.46M | -$3.73M | -$4.39M |
| Capital expenditure | $27,000 | — | — | $172,000 | $0 | $1,000 | $6,000 | -$534,000 |
| Free cash flow | -$5.06M | — | — | -$5.86M | -$4.33M | -$4.46M | -$3.73M | -$3.85M |
| Investing cash flow | -$27,000 | — | — | -$172,000 | $0 | -$1,000 | -$6,000 | $534,000 |
| Financing cash flow | -$51,000 | -$109,000 | $27.57M | $6.04M | $2.60M | $4.44M | $3.55M | $4.91M |
| Depreciation & amortization | $75,000 | $74,000 | $73,000 | $80,000 | $76,000 | $85,000 | $61,000 | $48,000 |
| Stock-based compensation | $307,000 | $214,000 | $239,000 | $179,000 | $172,000 | $146,000 | $160,000 | $153,000 |
| Dividends paid | — | — | — | -$1,000 | $0 | $607,000 | $1.21M | $614,000 |
Free plan shows the latest 8 periods; Pro shows all 23 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.